Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

H. Lundbeck Management

Management Kriterienprüfungen 1/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Charl van Zyl

Geschäftsführender

kr.39.6m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	6.8%
Amtszeit als Geschäftsführer	less than a year
Eigentum des Geschäftsführers	n/a
Durchschnittliche Amtszeit des Managements	1.8yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	3.3yrs

Jüngste Management Updates

Recent updates

These 4 Measures Indicate That H. Lundbeck (CPH:HLUN B) Is Using Debt Safely

Jun 05

H. Lundbeck (CPH:HLUN B) Will Pay A Larger Dividend Than Last Year At DKK0.70

Mar 07

H. Lundbeck (CPH:HLUN B) Has Announced That It Will Be Increasing Its Dividend To DKK0.70

Feb 22

H. Lundbeck A/S Just Missed Earnings - But Analysts Have Updated Their Models

Feb 10

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Charl van Zyl im Vergleich zu den Einnahmen von H. Lundbeck verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Mar 31 2024	n/a	n/a	kr.2b
Dec 31 2023	kr.40m	kr.3m	kr.2b

Vergütung im Vergleich zum Markt: CharlDie Gesamtvergütung ($USD5.76M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt Danish ($USD2.91M).

Entschädigung vs. Einkommen: Unzureichende Daten, um die Vergütung von Charl mit der Unternehmensleistung zu vergleichen.

Geschäftsführer

Charl van Zyl (57 yo)

less than a year

Amtszeit

kr.39,600,000

Vergütung

Mr. Charl van Zyl served as Executive Vice President Neurology Solutions & Head of EU/International at UCB SA since February 2020 until June 2023. He serves as President and Chief Executive Officer of H. L...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Charl van Zyl	President & CEO	less than a year	kr.39.60m	keine Daten
Joerg Hornstein	CFO & Executive VP of Corporate Functions	1.8yrs	kr.10.90m	0.0023% DKK 811.0k
Lars Bang	Executive Vice President of Product Development & Supply	5.4yrs	kr.10.10m	0.038% DKK 13.7m
Per Luthman	Executive Vice President of Research & Development	5.4yrs	kr.11.30m	0.014% DKK 5.0m
Tarek Samad	Senior VP & Head of Research	3.1yrs	keine Daten	keine Daten
Palle Olesen	Chief Specialist & VP of Investor Relations	no data	keine Daten	keine Daten
Tine Hansen	Senior Vice President of Corporate Communications & Public Affairs	less than a year	keine Daten	keine Daten
Dianne Holto	Executive Vice President of People & Organization	less than a year	keine Daten	keine Daten
Ole Chrintz	Senior Vice President of International Markets	no data	keine Daten	keine Daten
Rupert Sandbrink	Senior VP & Head of Clinical Development	2.4yrs	keine Daten	keine Daten
Bjorn Mogensen	Senior Vice President of Group Finance	1.8yrs	keine Daten	keine Daten
Jose Molinuevo	VP & Head of Experimental Medicine	no data	keine Daten	keine Daten

1.8yrs

Durchschnittliche Betriebszugehörigkeit

58.5yo

Durchschnittliches Alter

Erfahrenes Management: HLUN BDas Führungsteam des Unternehmens gilt nicht als erfahren (1.8 Jahre durchschnittliche Betriebszugehörigkeit), was auf ein neues Team schließen lässt.

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Lars Rasmussen	Independent Chairman	11.4yrs	kr.1.70m	0.010% DKK 3.6m
Lene Skole-Sorensen	Deputy Chairman	9.4yrs	kr.1.20m	0.0062% DKK 2.2m
Jeffrey Berkowitz	Independent Director	6.3yrs	kr.1.20m	keine Daten
Lars Holmqvist	Director	9.4yrs	kr.600.00k	0.0076% DKK 2.7m
Jakob Riis	Director	1.3yrs	kr.450.00k	0.0055% DKK 2.0m
Ilse Wenzel	Independent Director	3.3yrs	kr.70.00k	keine Daten
Santiago Arroyo	Independent Director	3.3yrs	kr.1.00m	keine Daten
Camilla Andersson	Employee Representative Director	2.3yrs	kr.400.00k	0.00010% DKK 35.7k
Dorte Clausen	Employee Representative Director	2.3yrs	kr.400.00k	0.00011% DKK 39.3k
Hossein Armandi	Employee Representative Director	2.3yrs	kr.400.00k	keine Daten
Lasse Skibsbye	Employee Representative Director	2.3yrs	kr.400.00k	keine Daten

3.3yrs

Durchschnittliche Betriebszugehörigkeit

58yo

Durchschnittliches Alter

Erfahrener Vorstand: HLUN BDie Vorstandsmitglieder gelten als erfahren (3.2 Jahre durchschnittliche Amtszeit).

H. Lundbeck Management

Management Kriterienprüfungen 1/4

Wichtige Informationen

Jüngste Management Updates

H. Lundbeck A/S Appoints Announces the Appointment of Maria Alfaiate as EVP, Commercial and Corporate Strategy, Effective 1 August 2024

H. Lundbeck A/S Announces Management Appointments

Key Executive recently bought kr.751k worth of stock

Less than half of directors are independent

H. Lundbeck A/S Appoints Dianne Holto as EVP, People & Organization, Effective from April 1, 2024

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

Recent updates

Lundbeck Presents Innovative First in Human Trial Design of Lu AG13909 for Potential Treatment of Congenital Adrenal Hyperplasia

These 4 Measures Indicate That H. Lundbeck (CPH:HLUN B) Is Using Debt Safely

H. Lundbeck A/S to Report Q4, 2024 Results on Feb 05, 2025

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

H. Lundbeck A/S Provides Earnings Guidance for the Year 2024

H. Lundbeck A/S Appoints Announces the Appointment of Maria Alfaiate as EVP, Commercial and Corporate Strategy, Effective 1 August 2024

Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD

Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S Announces Approval in the EU for the Maintenance Treatment of Schizophrenia

H. Lundbeck A/S Announces Management Appointments

H. Lundbeck A/S Announces Potential First-In-Class Therapy for Migraine Prevention Enters Advanced Clinical Stage

Upcoming dividend of kr.0.70 per share

H. Lundbeck (CPH:HLUN B) Will Pay A Larger Dividend Than Last Year At DKK0.70

H. Lundbeck A/S Proposes Dividend for the Accounting Year 2023

H. Lundbeck (CPH:HLUN B) Has Announced That It Will Be Increasing Its Dividend To DKK0.70

Key Executive recently bought kr.751k worth of stock

H. Lundbeck A/S Just Missed Earnings - But Analysts Have Updated Their Models

Less than half of directors are independent

H. Lundbeck A/S Appoints Dianne Holto as EVP, People & Organization, Effective from April 1, 2024

Lundbeck Announces Supportive Phase II Results with Lu Af82422 in the Treatment of Multiple System Atrophy from the Amulet Trial

H. Lundbeck A/S to Report Nine Months, 2024 Results on Nov 13, 2024

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

H. Lundbeck A/S Announces New Clinical Data Supporting the Efficacy and Tolerability of Lu AG09222 for the Preventive Treatment of Migraine At the International Headache Congress 2023 in Seoul, Korea

Lundbeck and Otsuka Announce Topline Results from Two Phase III Trials of Brexpiprazole as Combination Therapy with Sertraline for the Treatment of Post-Traumatic Stress Disorder in Adults

H. Lundbeck A/S Announces Elise Hauge Executive Vice President, People and Communication Decides to Depart

H. Lundbeck A/S to Report Q4, 2023 Results on Feb 07, 2024

H. Lundbeck A/S Raises Earnings Guidance for the Year 2023

H. Lundbeck A/S Appoints Charl Van Zyl as New President

H. Lundbeck A/S Announces New Data Confirming Long-Term Benefit of Treatment with Vyepti® (Eptinezumab) in Migraine Prevention

H. Lundbeck A/S and Otsuka Pharmaceutical, Co. Ltd. Announce U.S. Food and Drug Administration Approval of sNDA for Rexulti®? (Brexpiprazole) for the Treatment of Agitation Associated with Dementia Due to Alzheimer's Disease

H. Lundbeck A/S Proposes Dividend for 2022

H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2023

H. Lundbeck A/S Appoints Thomas Gibbs as Executive Vice President and Head of Lundbeck in United States

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S Announce FDA Acceptance and Priority Review of sNDA for Brexpiprazole for the Treatment of Agitation Associated With Alzheimer’s Dementia

H. Lundbeck A/S to Report Nine Months, 2023 Results on Nov 08, 2023

H. Lundbeck A/S, Annual General Meeting, Mar 21, 2023

H. Lundbeck A/S (Lundbeck)Announces Positive Data Showing Trintellix/Brintellix® (vortioxetine)

Otsuka and Lundbeck Announce U.S. FDA Acceptance of New Drug Application for Aripiprazole 2-Month, Ready-To-Use, Long-Acting Injectable to Treat Schizophrenia and Bipolar I Disorder in Adults

H. Lundbeck A/S Provides Earnings Guidance for the Financial Year 2022

H. Lundbeck A/S Revises Earnings Guidance for the Fiscal Year 2022

H. Lundbeck A/S and Otsuka Pharmaceutical Announce Positive Results Showing Reduced Agitation in Patients with Alzheimer's Dementia Treated with Brexpiprazole

European Medicines Agency Commences Review of Aripiprazole 2-Month Long-Acting Injectable for the Maintenance Treatment of Schizophrenia in Adult Patients Stabilised with Aripiprazole

H. Lundbeck A/S Announces Results from the Deliver Study with Vyepti

H. Lundbeck A/S(CPSE:LUN) dropped from OMX Nordic All-Share Index

Analyse der Geschäftsführervergütung

Geschäftsführer

Amtszeit

Vergütung

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter